ketorolac and Diabetes Mellitus
ketorolac has been researched along with Diabetes Mellitus in 3 studies
Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"To evaluate the additional effect of ketorolac eye drops on therapeutic effects of intravitreal Bevacizumab in patients with diabetic macular edema (DME) METHODS: In a randomized clinical trial, 50 patients with center involved DME (macular thickness ≥ 300 microns accompanied by decreased VA (24 < BCVA ≤ 70 ETDRS letters) were enrolled consecutively and randomized 1:1 to receive either bevacizumab plus topical ketorolac (25 patients) or bevacizumab plus artificial tears (25 patients)." | 9.41 | Topical ketorolac as an adjunctive treatment with intravitreal bevacizumab in the management of diabetic macular edema: A double-masked placebo-controlled randomized clinical trial. ( Entezari, M; Hassanpour, K; Karimi, S; Niazpour Moez, R; Nikkhah, H; Ramezani, A; Yaseri, M, 2021) |
"To evaluate the additional effect of ketorolac eye drops on therapeutic effects of intravitreal Bevacizumab in patients with diabetic macular edema (DME) METHODS: In a randomized clinical trial, 50 patients with center involved DME (macular thickness ≥ 300 microns accompanied by decreased VA (24 < BCVA ≤ 70 ETDRS letters) were enrolled consecutively and randomized 1:1 to receive either bevacizumab plus topical ketorolac (25 patients) or bevacizumab plus artificial tears (25 patients)." | 5.41 | Topical ketorolac as an adjunctive treatment with intravitreal bevacizumab in the management of diabetic macular edema: A double-masked placebo-controlled randomized clinical trial. ( Entezari, M; Hassanpour, K; Karimi, S; Niazpour Moez, R; Nikkhah, H; Ramezani, A; Yaseri, M, 2021) |
Research
Studies (3)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 2 (66.67) | 2.80 |
Authors
Authors | Studies |
---|---|
Mohammad-Rabei, H | 1 |
Sabbaghi, H | 1 |
Emamverdi, M | 1 |
Karimi, S | 2 |
Ramezani, A | 2 |
Nikkhah, H | 2 |
Kheiri, B | 1 |
Yaseri, M | 2 |
Sheibani, K | 1 |
Bahreini, R | 1 |
Niazpour Moez, R | 1 |
Entezari, M | 1 |
Hassanpour, K | 1 |
Yılmaz, U | 1 |
Küçük, E | 1 |
Ulusoy, DM | 1 |
Özköse, A | 1 |
Ataş, M | 1 |
Demircan, S | 1 |
Yuvacı, I | 1 |
Trials
3 trials available for ketorolac and Diabetes Mellitus
Article | Year |
---|---|
The effect of topical ketorolac tromethamine on macular thickening after phacoemulsification in diabetic patients.
Topics: Diabetes Mellitus; Diabetic Retinopathy; Humans; Ketorolac; Ketorolac Tromethamine; Macular Edema; P | 2023 |
Topical ketorolac as an adjunctive treatment with intravitreal bevacizumab in the management of diabetic macular edema: A double-masked placebo-controlled randomized clinical trial.
Topics: Angiogenesis Inhibitors; Bevacizumab; Diabetes Mellitus; Diabetic Retinopathy; Humans; Intravitreal | 2021 |
The assessment of changes in macular thickness in diabetic and non-diabetic patients: the effect of topical ketorolac on macular thickness change after ND:YAG laser capsulotomy.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Ca | 2016 |